Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (Sunshine Guojian),whose predecessor is Shanghai CP Guojian Pharmaceutical Co., Ltd. jointly invested in 2002 as a biomedical high-tech enterprise by China CITIC Group and the Lansheng Guojian Pharmaceutical Co., Ltd., is established in 2015 and integrated into the Sunshine Pharmaceutical Group, a Hong Kong listed company, upon equity investment. Over the past decade, Sunshine Guojian has committed to the R&D, pilot scale development and industrialization of antibody drugs. The company has built up a self-owned antibody drug discovery platform with core technologies and know-hows, as well as led or participated in drafting of national standards in antibody drug quality control. Sunshine Guojian’s antibody drug production lines (3*750L and 2*3000L) has been granted the GMP certificate by CFDA and its new production lines (6*5000L) by EU standards were completed construction and realized successful trial production in 2015, leading in production scale and quality control in the domestic industry. As a leading player in the field of domestic pharmaceutical antibody, the company provides targeted drugs for autoimmune diseases, cancer, organ transplantation immunosuppression treatment, with a sustainable capability of drug innovation and development.